Kintor’s Cosmetics-Driven Revenue Soars but Loss Widens on Pipeline Shift

Kintor Pharmaceutical Ltd ( (HK:9939) ) has issued an update.

Kintor Pharmaceutical reported a surge in revenue to RMB32.7 million for 2025, up 554% year-on-year, driven mainly by global sales of its KOSHINÉ high-end cosmetics brand, where core compound KX-826 is a key ingredient and livestream e-commerce is boosting demand. The company plans to use cash flow from cosmetics sales to fund development and commercialization of core dermatology pipelines KX-826 and GT20029, while continuing to promote its cosmetic products worldwide.

Despite the strong top-line growth, the group’s net loss widened 28.8% to RMB200.1 million in 2025, reflecting higher administrative expenses and impairment losses from suspending non-dermatology pipelines. R&D spending rose 11.9% to RMB87.4 million as Kintor intensified investment in its core dermatology assets, while selling and marketing costs climbed on cosmetics promotion; the company ended the year with RMB32.7 million in cash, RMB50 million in unused bank facilities, implemented new financing plans to support trials, and again opted against paying a final dividend.

The most recent analyst rating on (HK:9939) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Kintor Pharmaceutical Ltd stock, see the HK:9939 Stock Forecast page.

More about Kintor Pharmaceutical Ltd

Kintor Pharmaceutical Limited is a Cayman Islands–incorporated biopharmaceutical company listed in Hong Kong that focuses on developing dermatology treatments, notably its core drug candidates KX-826 and GT20029. It is also expanding a high-end cosmetics business under the KOSHINÉ brand, leveraging livestream e-commerce to commercialize products that incorporate its proprietary ingredients and support its broader R&D pipeline.

Average Trading Volume: 4,139,574

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.43B

Find detailed analytics on 9939 stock on TipRanks’ Stock Analysis page.